Attention: Restrictions on use of AUA, AUAER, and UCF content in third party applications, including artificial intelligence technologies, such as large language models and generative AI.
You are prohibited from using or uploading content you accessed through this website into external applications, bots, software, or websites, including those using artificial intelligence technologies and infrastructure, including deep learning, machine learning and large language models and generative AI.
Bridging Surgery and Systemic Therapy: ctDNA-Guided Management Across GU Cancers
December 16, 2025 | 7:00 PM ET
Learn more about tumor-informed ctDNA testing (Signatera™) and its expanding role in guiding clinical decisions across the genitourinary oncology continuum. Experts Dr. Shilpa Gupta and Dr. Laura Bukavina from Cleveland Clinic will discuss the evolving role of ctDNA testing from the surgical to systemic setting, featuring new insights from the landmark IMvigor011 phase III trial and key data from recent ESMO and ASCO presentations.
Meet the Speakers
Adam C. ElNaggar, MD, FACOG
Moderator
Senior Scientist, Oncology Medical Affairs, Natera
Dr. Adam ElNaggar joined Natera in 2021 and is the Senior Medical Director for genitourinary, gynecologic, and hereditary cancers. Prior to this, he was at University of Tennessee West Cancer Center and Research Institute where he served as Director of Gynecologic Cancer Research and Associate Fellowship Director.
Dr. ElNaggar earned his medical degree at Indiana University School of Medicine and completed his residency in obstetrics and gynecology at the University of Tennessee Health Science Center in Memphis, TN. He then completed his fellowship in gynecologic oncology at The Ohio State University Comprehensive Cancer Center.
Laura Bukavina, MD, MPH
Assistant professor of Urologic Oncology, Cleveland Clinic Glickman Urologic Institute, and translational science lead in GU oncology, Cleveland Clinic Lerner College of Medicine
Dr. Laura Bukavina is a urologic oncologist and translational research lead for genitourinary oncology at Cleveland Clinic, with a primary focus on urothelial bladder cancer. Her work centers on surgical trials in NMIBC and MIBC, with integration next-generation sequencing and tumor-informed ctDNA/utDNA assays into trial design to refine risk stratification, guide intravesical versus systemic therapy, and personalize perioperative management for patients with high-risk NMIBC and MIBC.
Shilpa Gupta, MD
Director, Genitourinary Medical Oncology, Cleveland Clinic
Dr. Gupta is a leading authority in urothelial and kidney cancers, with a focus on perioperative immunotherapy, biomarker-guided decision-making, and clinical trials that bridge medical oncology and surgical management.
This is a non-CME, company-led program developed and sponsored by Natera, intended for healthcare professionals only. The content of this company-directed program is not sponsored or endorsed by the American Urological Association (AUA).
